2-氨基-4-甲基吡啶,二恶酮利福霉素 以 甲醇,水 作为反应溶剂,化学反应 24.0H,反应生成 利福西亚胺 参考文献: Process For The Preparation Of Crystalline Forms Of Rifaximin[fr] Procédé De Préparation De Formes Cristallines De Rifaximine 标题: Process For The Preparation Of Crystalline Forms Of Rifaximin[fr] Procédé De Préparation De Formes Cristallines De Rifaximine 摘要:本发明涉及一种改进的工艺,用于制备以下结构式-1所表示的rifaximin化合物的晶体多晶形.
专利信息
专利号:US-2024197774-A1 优先权日:2021-04-16 标 题:Synthesis of Antimicrobial PVP-coated Bismuth Nanoparticles 发明人:LOPEZ-RIBOT JOSE; VAZQUEZ-MUNOZ ROBERTO 权利人:UNIV TEXAS 摘要:Described herein is a facile, fast, and economical method for the synthesis of BAL-mediated PVP-BiNPs, using basic laboratory instruments and reagents readily available in most laboratories.
专利号:US-11744867-B2 优先权日:2017-02-14 标 题 :Modulation of microbial synthesis of 4-ethylphenol and 4-ethylphenyl sulfate in behavior and disease 发明人:NEEDHAM BRITTANY D; MAZMANIAN SARKIS K; SHARON GIL; FUNABASHI MASANORI; FISCHBACH MICHAEL A; HSIAO ELAINE Y; PATTERSON PAUL H 权利人:CALIFORNIA INST OF TECHN; UNIV CALIFORNIA 摘要:Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset, or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject.
专利号:US-10899773-B2 优先权日:2014-12-19 标 题 :Total synthesis of trioxacarcin DC-45-A2 and preparation of trioxacarcin analogs 发明人:NICOLAOU KYRIACOS C; CAI QUAN 权利人:UNIV RICE WILLIAM M 摘要:In one aspect, the present invention provides novel derivatives of trioxacarin analogs of the formula (I) wherein the variables are as defined herein. The application also provides compositions, methods of treatment, and methods of synthesis thereof.
专利号:US-2016185745-A1 优先权日:2013-08-07 标题:Analogs of vinaxanthone and xanthofulvin, methods of synthesis, and methods of treatments thereof 发明人:SIEGEL DIONICIO; CHIN MATTHEW; ELIASEN ANDERS; AXELROD ABRAM 权利人:UNIV TEXAS 摘要:The present invention relates generally to methods of synthesis of vinaxanthone and xanthofulvin, novel analogs, and methods of use thereof.
专利号:US-10443047-B2 优先权日:2014-05-01 标题 :Increasing cellular lipid production by increasing the activity of diacylglycerol acyltransferase and decreasing the activity of triacylglycerol lipase 发明人:TSAKRAKLIDES VASILIKI; BREVNOVA ELENA E 权利人:NOVOGY INC 摘要:Disclosed are methods and compositions for increasing the triacylglycerol content of a cell by up-regulating diacylglycerol acyltransferase and down-regulating triacylglycerol lipase. In some embodiments, a DGA1 protein is expressed and a native TGL3 gene is knocked out, thereby increasing the synthesis of triacylglycerol and decreasing its consumption, respectively.
专利号:US-9693999-B2 优先权日:2011-01-26 标题:Small molecule RNase inhibitors and methods of use 发明人:DUNMAN PAUL M; OLSON PATRICK D; CHILDERS WAYNE 权利人:UNIV ROCHESTER; UNIV NEBRASKA; Temple University—Of the Commonwealth System of Higher Education 摘要:Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. Also described herein are methods of identifying compounds for treating or preventing a microbial infection.
1: Rifaximin (Zaxine): For the Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence in Patients ≥ 18 Years of Age [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul. Available from http://www.ncbi.nlm.nih.gov/books/NBK362587/ doi: 10.1002/phar.1712. Epub 2016 Mar 11. Review. doi: 10.1097/MD.0000000000002534. Review. doi: 10.1111/apt.13437. Review. doi: 10.1111/apt.13436. Review. doi: 10.1111/apt.13435. Review. doi: 10.1111/apt.13434. Review. doi: 10.3748/wjg.v21.i43.12322. Review. 9: Cash BD, Lacy BE, Rao T, Earnest DL. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? Expert Opin Pharmacother. 2016;17(3):311-22. doi: 10.1517/14656566.2016.1118052. Epub 2015 Dec 8. Review. Review. doi: 10.1016/j.mayocp.2015.04.016. Epub 2015 Jul 8. Review. doi: 10.2147/CEG.S67231. eCollection 2015. Review. 13: Laterza L, Ianiro G, Scoleri I, Landi R, Bruno G, Scaldaferri F, Gaetani E, Campanale M, Gasbarrini A. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opin Pharmacother. 2015 Mar;16(4):607-15. doi: 10.1517/14656566.2015.1007951. Epub 2015 Feb 1. Review. doi: 10.1007/s40265-014-0300-y. Review. doi: 10.1038/ja.2014.106. Epub 2014 Aug 6. Review. doi: 10.1111/apt.12803. Epub 2014 May 21. Review. doi: 10.2147/PPA.S41565. eCollection 2014. Review.
合成参考文献
参考文献:10.1124/mol.119.115964 摘要:Lee TD, Lee OW, Brimacombe KR, Chen L, Guha R, Lusvarghi S, Tebase BG, Klumpp-Thomas C, Robey RW, Ambudkar SV, Shen M, Gottesman MM, Hall MD. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular Pharmacology. 2019 Nov;96(5):629–40. doi: 10.1124/mol.119.115964.